InterStudy Publications, a division of Decision Resources, specializing in the managed care industry, announces the release of its Spring 2004 MSA Profiler database, which presents HMO data at the metropolitan statistical area (MSA) level. According to this new research, as of July 1, 2003, the Miami-Miami Beach-Kendall, Florida, MSA was the nation's most competitive HMO market. The top 5 plans in this market made up 64% of the market share, while 12 other plans competed for the remaining available lives.

"In addition to viewing the MSAs with the greatest competition, analysts can use this database to evaluate how potential mergers will affect specific MSAs," said Lance Wolkenbrod, database specialist for InterStudy Publications. "For example, in the case of the proposed merger of United and Oxford, the data shows that in the Edison, New Jersey, MSA, the merger would more than double United's market share."

About the MSA Profiler

The MSA Profiler database is the only credible source for nationwide HMO market share data at the MSA level. The MSA Profiler database can be used to assess the regional market presence of national managed care firms, align managed care salesforces, and identify areas of potential opportunity.

About InterStudy Publications

InterStudy Publications, a division of Decision Resources, offers data, directories, and analyses of the ever-evolving managed care industry. InterStudy tracks changes and trends in HMO and PPO services, enrollment, and profitability. Visit InterStudy Publications at

About Decision Resources

Decision Resources, Inc., ( is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Frank Sama    InterStudy Publications    781-296-2553 

SOURCE: InterStudy Publications

CONTACT: Frank Sama of InterStudy Publications, +1-781-296-2553,

Rituximab is the Most Promising Emerging Drug for Chronic Lymphocytic Leukemia

View Now